18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG

This article reviews possible use of F-18-labelled radiopharmaceuticals in oncology with positron emission tomography. The characteristics of various F-18-labelled compounds are proteins and peptides, those that bind to receptors, agents to assess hypoxia, and agents to evaluate gene therapy are highlighted. Furthermore, different F-18-labelled tissue specific agents are indicated for the detection and monitoring of various malignancies: melanoma, brain tumours, breast cancer, prostate cancer and colorectal cancer. F-18-fluorodeoxyglucose has been excluded from this summary. NUCL MED BIOL 27;2:103-112, 2000. (C) 2000 Elsevier Science Inc. All rights reserved.